Shatavari Dosage for Hormonal Balance: Trial Doses

Shatavari (Asparagus racemosus) — "she who possesses a hundred husbands" — is Ayurveda's premier women's herb, and 2025 brought the strongest human evidence it has ever had: three randomized trials of standardized extracts for perimenopausal symptoms, all reporting significant symptom reductions, with a fourth trial peer-reviewed in 2026. But the doses used in those trials are far lower than traditional powder doses. This guide maps the trial doses to traditional dosing, covers the evidence honestly, and flags the estrogen-sensitive safety caveats.

What Shatavari Is (and What Makes It "Hormonal")

Shatavari (Asparagus racemosus) root is classified in Ayurveda as a Stri Rasayana — a female rejuvenative — documented in the Charaka Samhita and Ashtanga Hridayam for over 2,000 years. Its relevance to hormonal balance comes from steroidal saponins called shatavarins, which the site's own remedy page notes have estrogenic activity via estrogen-receptor binding. The root also contains racemofuran and asparagamine A (antioxidant, immunomodulatory) and is a traditional galactagogue (Gupta & Shaw 2011: prolactin rose more than three-fold vs control in 60 lactating mothers; Birla et al. 2022: increased breast milk output in a double-blind RCT).

The key tension: phytoestrogenic activity is mostly demonstrated in preclinical work — no human trial has directly measured estrogen-receptor binding or activation by shatavarins (every such claim traces to in-vitro studies, e.g. Shatavarin IV binding ERα/ERβ). The new human trials give us symptom outcomes, not receptor-binding confirmation — so the honest framing is "trial-supported symptom relief," not "proven estrogen modulation."

The 2025 Trial Wave: What the Studies Actually Used

Three randomized, double-blind, placebo-controlled trials of standardized shatavari extracts for perimenopausal symptoms were published in 2025 — a landmark year for this herb — and a fourth was peer-reviewed in 2026. Note that all used proprietary standardized extracts, and industry funding is involved in some (see sponsorship notes below):

*SRI-81 (Mahajan et al., 2025, International Journal of Women's Health 17:4057–4073, DOI: 10.2147/IJWH.S544267).* 80 perimenopausal women aged 40–55 received 300 mg/day of SRI-81 shatavari root extract (standardized to a minimum of >10% total shatavarins by HPLC) or placebo for 8 weeks. Total Menopause Rating Scale (MRS) scores fell 42.6% in the shatavari group vs 5.5% with placebo; perceived stress scores fell ~30%; hot-flash scores fell 26% vs 7% placebo (percentages derived from the paper's published mean-change tables, per-protocol). No adverse events; liver and kidney markers remained stable. The extract was supplied by the manufacturer (Ixoreal BioMed, Los Angeles); the paper formally declares no grant funding and no conflicts of interest.

*CL22209 / Xeya Modern Shatavari (Yadav et al., Functional Foods in Health and Disease 2025;15(7):415–443, DOI: 10.31989/ffhd.v15i7.1684, published July 22, 2025). 75 perimenopausal women aged 40–50 received 50 mg or 100 mg/day of an extract standardized to not less than 15% total shatavarins — or placebo — for 120 days. Hot-flash scores (frequency × severity composite, HFWWS) fell 27.6% and 39.8% in the 50 mg and 100 mg groups (vs a 7.7% increase* with placebo); MRS scores fell 51.4% and 72.9% (vs 22.9% placebo); ovarian follicle count rose 34.4% and 51.9%; psychological symptoms improved ~74%. Notably, the doses here are strikingly low — 50–100 mg/day — because the extract is concentrated to 15% shatavarins. This trial was industry-funded by the extract manufacturer (Chemiloids Life Sciences Pvt. Ltd) — the authors declared no conflicts of interest — so treat the effect sizes with the usual caution for industry-funded trials.

*Ademola et al. (2025, Frontiers in Reproductive Health 7:1654503, DOI: 10.3389/frph.2025.1654503, published Nov 27, 2025).* 135 women aged 45–65 with menopausal symptoms received shatavari root extract alone, a shatavari + ashwagandha combination, or placebo for 8 weeks (three-arm trial). Primary endpoint: MRS change at weeks 4 and 8; secondary: perceived stress, quality of life, hot flashes, serum hormones, and safety. The broader age range (45–65) means this population likely includes postmenopausal women, unlike the strictly perimenopausal SRI-81 and CL22209 trials.

*aspurūs (Surampalli et al., Journal of Dietary Supplements 2026;23(4):490–518, DOI: 10.1080/19390211.2026.2689348, epub July 31, 2026; industry announcement Aug 26, 2026).* 150 perimenopausal women aged 38–54 received 500 mg/day of aspurūs extract or placebo for 12 weeks (84 days; 145 completed). The primary endpoint (Menopause Symptom Severity Inventory, MSSI-38) showed statistically significant reductions (p<0.001) in both frequency and intensity scores at day 84; serum FSH and LH declined significantly (p<0.05); no adverse events were reported. The 500 mg/day dose delivered roughly 25 mg total shatavarins (~5% shatavarins). The study was funded by the extract maker (Waleria Healthtech) — treat the effect sizes with the usual caution for industry-funded trials.

What this means for dosing: The trial doses cluster at 50–500 mg/day of standardized extract — far below traditional powder doses (up to 2 g/day), because standardized extracts concentrate the shatavarins. You cannot convert "300 mg of 10% extract" to "X grams of powder" without knowing the powder's shatavarin content, which is essentially never stated on consumer labels.

Shatavari Dosage by Goal: Trial Doses vs Traditional Doses

The practical takeaway: If you are buying a standardized extract, look for a stated shatavarin percentage and stay within the 50–500 mg/day range the trials used. If you are using traditional root powder, 500 mg–1 g/day with warm milk is the traditional and site-consistent range — and do not assume it is "equivalent" to a standardized extract.

Standardization: Shatavarins and Why They Matter

The new trials converge on one standardization metric: shatavarin content. SRI-81 was standardized to a minimum of >10% total shatavarins (HPLC); CL22209 to not less than 15%; aspurūs delivered ~25 mg shatavarins at 500 mg/day (~5%). This is now the quality marker to look for on labels. Products that list only "shatavari root powder 500 mg" with no shatavarin or saponin figure cannot be compared to the trial extracts — and most of the traditional-dose literature never measured them.

One caveat from the Sep-2026 review of the site's own shatavari-vs-ashwagandha article: phytoestrogenic activity framing should stay precautionary — "steroidal saponins with reported estrogen-receptor binding (preclinical)" rather than "natural estrogen." The trials measured symptom scores, not hormone-receptor activation.

How Long Until It Works

From the trial timelines:

• First signals: The aspurūs press announcement (Aug 26, 2026) and the company's statements to trade press reported some improvements appearing within 2 weeks (Nutritional Outlook, Aug 28, 2026) — but the peer-reviewed primary endpoint was 12 weeks (84 days), and press-release timelines deserve skepticism.
• Meaningful change: Mahajan 2025 measured the headline results at 8 weeks; CL22209 at 120 days. A reasonable expectation frame: 8–12 weeks of consistent daily use before judging symptom change.
• Traditional framing: Shatavari is a Rasayana — a tonic meant for sustained use, not an acute fix. No published trial has tested courses longer than 120 days — the CL22209 trial at 120 days is the longest found in indexed literature and trial registries.

Perimenopause vs Menopause vs PCOS: What the Evidence Covers

• Perimenopause: The SRI-81, CL22209, and aspurūs trials enrolled perimenopausal women (ages 38–55); the Ademola trial enrolled women 45–65 with menopausal symptoms, likely including postmenopausal women. The Mahajan authors explicitly noted that efficacy beyond the perimenopausal population (i.e., fully postmenopausal women) still needs dedicated trials.
• Postmenopause: One dedicated postmenopausal RCT now exists (Mishra et al., Avicenna Journal of Phytomedicine, epub ahead of print, received Feb 2025): 214 postmenopausal women received ARova5X — a hydroalcoholic shatavari root extract standardized to 5% shatavarins — at 250 mg/day or placebo for 90 days, with endpoints centered on sexual function, menopausal symptoms, and oxidative stress. Postmenopausal data is emerging, but the perimenopause symptom-scale results do not automatically transfer.
• PCOS: One 84-day RCT (CL22209, 100 mg/day, n=60, ages 20–35; Kondamudi et al., Food & Nutrition Research 2025;69:13244, DOI: 10.29219/fnr.v69.13244, published Dec 23, 2025) reported improved ovarian morphology (ovarian volume −21% vs placebo; cyst size −41%; follicle number −21%, all P<0.0001) with modest changes in menstrual patterns and exploratory indications of improved insulin sensitivity. Primary endpoint: change in ovarian volume. Industry-funded by Chemiloids Life Sciences Pvt. Ltd (authors declared no conflicts). Exploratory, not established.
• Fertility/lactation: Traditional use is strong; human data exists for lactation — Gupta & Shaw (Iranian Journal of Pharmaceutical Research 2011) found a greater-than-three-fold rise in prolactin vs control in 60 lactating mothers (p<0.05), and Birla et al. (Cureus 2022) measured increased breast milk output in a double-blind RCT (a 2026 single-arm trial reported milk volume +65%, 310→511 mL/day). Caveat: one older study (Sharma et al. 1996) found no prolactin rise with a polyherbal shatavari formula — the evidence is inconsistent.

Safety: Estrogen-Sensitive Conditions and Interactions

This is the section that matters most, because shatavari's mechanism is its risk:

• Estrogen-sensitive conditions — avoid or use only with medical supervision. The site's own remedy page is explicit: avoid with estrogen-receptor-positive cancers (breast, uterine); it could theoretically enhance estrogen therapy or hormonal birth control pills (no human interaction data — precautionary). Given the phytoestrogenic activity, anyone with a history of hormone-sensitive cancer should not self-supplement.
• Excess dosing. No established overdose threshold or excess-dose toxicity profile exists in authoritative sources — claims of fluid retention, weight gain, or heavy menstrual bleeding at “>4 g/day” are unsourced precautionary statements, not established effects (WebMD notes bloating and dizziness in some studies, and states there is no evidence shatavari causes weight gain). Stay within traditional ranges (500 mg–2 g/day powder).
• Pregnancy and breastfeeding. Pregnancy is an avoid-or-supervise zone, not a gray area: a rat teratogenicity study (Goel et al., Indian Journal of Experimental Biology 2006) found methanolic shatavari root extract caused fetal resorption and malformations, concluding it "should be used in pregnancy cautiously," and Australian Prescriber (2018) advises it is "prudent to avoid Shatavari in the first trimester (during organogenesis)"; WebMD advises avoiding shatavari in pregnancy. Lactation has the most human data (galactagogue effect) — but use then too should follow clinician guidance.
• Blood sugar. Antihyperglycemic activity is shown in animal studies only; no human interaction data exists (WebMD: interactions unknown) — monitor if taking diabetes medications and discuss with your clinician.
• Diuretics. A diuretic effect is asserted in Ayurvedic tradition, not quantified clinically; no human interaction data exists. Discuss with your clinician before combining with diuretics.
• Trial safety note: Across the trials (n≈440 combined), no adverse events were reported where safety data was published (Mahajan 2025; aspurūs), and liver/kidney markers stayed stable — but all trials were ≤120 days. Long-term safety data does not exist.

Dosage Summary Table

📢 Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any new supplement. Sources are linked for verification.

Explore the Full Remedy Database

Browse 500+ organic alternatives for health, wellness, and natural living.